Clinical scale Cellply is a Bologna-based biotechnology company focused on single-cell analytical tools for cancer immunotherapies and cell-based biotherapeutics, highlighting a potential market need for end-to-end potency characterization and immunophenotyping platforms.

Automated platform Their flagship VivaCyte platform offers fully automated, standalone single-cell resolution capabilities, presenting a sales angle for labs seeking integrated, turnkey solutions to streamline R&D and quality control in cell therapy development.

Funding momentum With $20M in funding and recent rounds totaling several million euros, Cellply demonstrates investor validation and growth potential, signaling readiness for customer acquisition in EU and international markets.

Emerging expansion Recent product launches and leadership changes, including a new CEO in 2023 and VivaCyte introductions in 2024, indicate a company in growth mode open to partnerships, pilots, and co-development opportunities.

Targeted value The platform’s integration of potency analysis with immunophenotyping aligns with demand in cell therapies and cancer immunotherapies for quality control, monitoring clinical response, and accelerating R&D— ideal for collaboration with biotechs and CROs seeking advanced single-cell analytics.